MVRIX has completed a Series B investment round worth 8 billion won.

This investment will be used to develop the in vivo CAR-T candidate 'MIC-001' based on MVRIX's proprietary targeted mRNA delivery platform 'Navibody'.

MVRIX will pursue non-clinical validation and production process development to lay the foundation for clinical entry.

We sincerely thank our investors and partners who have believed in MVRIX's technology and potential and have joined us.